These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7842819)

  • 1. Hemodialysis removal of norfloxacin.
    Lau AH; Tang I; Fitzloff J; Jain R
    Chemotherapy; 1994; 40(6):369-73. PubMed ID: 7842819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodialysis of acetaminophen in uremic patients.
    Marbury TC; Wang LH; Lee CS
    Int J Artif Organs; 1980 Sep; 3(5):263-6. PubMed ID: 7461859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of dialyzer geometry on blood coagulation and biocompatibility.
    Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R
    Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide.
    Wang LH; Lee CS; Majeske BL; Marbury TC
    Clin Pharmacol Ther; 1981 Mar; 29(3):365-72. PubMed ID: 7471607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence evaluation of norfloxacin tablets based on in vitro - in vivo correlation.
    Khiljee S; Ahmad M; Murtaza G; Madni A; Akhtar N; Akhtar M
    Pak J Pharm Sci; 2011 Oct; 24(4):421-6. PubMed ID: 21959800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
    Lee CS; Wang LH; Marbury TC; Bruni J; Perchalski RJ
    Clin Toxicol; 1980 Oct; 17(3):429-38. PubMed ID: 7449356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of ceftriaxone in hemodialysis].
    Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of dyphylline elimination by uremic patients.
    Lee CC; Wang LH; Majeske BL; Marbury TC
    J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norfloxacin concentrations in seminal plasma measured by HPLC.
    Bologna M; Vaggi L; Flammini D; Carlucci G; Francavilla F
    Drugs Exp Clin Res; 1985; 11(11):801-4. PubMed ID: 3836861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biocompatibility of hemodialysis membranes: evaluation in an ovine model.
    Burhop KE; Johnson RJ; Simpson J; Chenoweth DE; Borgia J
    J Lab Clin Med; 1993 Feb; 121(2):276-93. PubMed ID: 8433041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers.
    Kumar A; Mann HJ; Keshtgarpour M; Flynn MA; Deng H; Far AR; Parr TR; Moriarty SR
    Int J Artif Organs; 2011 Nov; 34(11):1067-74. PubMed ID: 22183520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphenol A in chronic kidney disease.
    Krieter DH; Canaud B; Lemke HD; Rodriguez A; Morgenroth A; von Appen K; Dragoun GP; Wanner C
    Artif Organs; 2013 Mar; 37(3):283-90. PubMed ID: 23145999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodialysis of mefenamic acid in uremic patients.
    Wang LH; Lee CS; Marbury TC
    Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of primidone elimination by uremic patients.
    Lee CS; Marbury TC; Perchalski RT; Wilder BJ
    J Clin Pharmacol; 1982 Jul; 22(7):301-8. PubMed ID: 7107978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo.
    Sombolos K; Tsitamidou Z; Kyriazis G; Karagianni A; Kantaropoulou M; Progia E
    Am J Nephrol; 1997; 17(5):406-12. PubMed ID: 9382156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebound kinetics of beta2-microglobulin after hemodialysis.
    Leypoldt JK; Cheung AK; Deeter RB
    Kidney Int; 1999 Oct; 56(4):1571-7. PubMed ID: 10504510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes.
    Akkan AG; Mutlu I; Ozyazgan S; Gök A; Yigit U; Ozüner Z; Senses V; Pekel H
    Int J Clin Pharmacol Ther; 1997 May; 35(5):214-7. PubMed ID: 9174877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dialyzer fiber bundle volume during hemodialysis using large-surface dialyzers.
    Leblanc M; Lafrance JP; Renald A
    ASAIO J; 2006; 52(6):646-51. PubMed ID: 17117054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug.
    Brown SA; Cooper J; Gauze JJ; Greco DS; Weise DW; Buck JM
    Am J Vet Res; 1990 Jul; 51(7):1065-70. PubMed ID: 2389884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.